8,728 results on '"GENITAL warts"'
Search Results
2. Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (TheraVACCS)
- Author
-
University of Stellenbosch and Professor Greta Dreyer, Professor
- Published
- 2024
3. Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
- Published
- 2024
4. HPV integration and cervical cancer: a failed evolutionary viral trait.
- Author
-
Molina, Mariano A., Steenbergen, Renske D.M., Pumpe, Anna, Kenyon, Angelique N., and Melchers, Willem J.G.
- Subjects
- *
HUMAN papillomavirus , *CELL transformation , *MEDICAL screening , *ONCOGENIC proteins , *PROTEIN overexpression , *GENITAL warts , *CERVICAL intraepithelial neoplasia , *TUMOR suppressor genes - Abstract
Human papillomavirus (HPV) infections are common among reproductive-age women. The use of primary HPV testing has proven more effective in identifying high-grade precancerous lesions, leading to better clinical outcomes in women. HPV integration into the host genome is a multifactorial process. Various host, viral, and environmental cofactors, such as smoking, cervicovaginal microbiota, estrogen levels, and coinfection with HIV, influence this process. The disruption of the E2 gene is identified as a hallmark of HPV integration and cancer development, leading to the overexpression of oncogenic proteins (E6/E7) and the formation of superenhancers, thereby contributing to cellular transformation and cervical neoplasia. HPV integration results in host genomic instability, chromosomal rearrangements, loss of function in tumor suppressor genes, and epigenome dysregulation. Countless efforts have been made to eradicate cervical cancer worldwide, including improving disease screening and human papillomavirus (HPV) vaccination programs. Nevertheless, cervical cancer still claims the lives of more than 300 000 women every year. Persistent infections with high-risk HPV genotypes 16 and 18 are the main cause of cancer and may result in HPV integration into the host genome. The central dogma is that HPV integration is an important step in oncogenesis, but in fact, it impedes the virus from replicating and spreading. HPV causing cervical cancer can therefore be perceived as a failed evolutionary viral trait. Here we outline the occurrence and mechanisms of HPV integration and how this process results in oncogenic transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Time trends in the clinical management of cervical intraepithelial neoplasia grade 2: A Danish register‐based study.
- Author
-
Eriksen, Dina Overgaard, Randrup, Tina Hovgaard, Lycke, Kathrine Dyhr, Damgaard, Rikke Kamp, Kahlert, Johnny, Ostenfeld, Eva Bjerre, Jensen, Pernille Tine, Wentzensen, Nicolas, Clarke, Megan A., and Hammer, Anne
- Subjects
- *
CERVICAL intraepithelial neoplasia , *WATCHFUL waiting , *CLINICAL indications , *CHILDBEARING age , *HUMAN papillomavirus vaccines , *GENITAL warts - Abstract
Introduction: Active surveillance for cervical intraepithelial neoplasia grade 2 (CIN2) has been implemented recently in many countries, including the Nordic countries. In Denmark, the only eligibility criterion for active surveillance for CIN2 is that the woman should be of reproductive age. With this study, we aimed to evaluate clinical and socioeconomic characteristics in women with CIN2 managed by active surveillance or large loop excision of the transformation zone (LLETZ) and to evaluate temporal changes in the clinical management of CIN2. Material and Methods: We conducted a Danish nationwide study using data from healthcare registries. All female residents aged 18–40 years, diagnosed with incident CIN2 from January 1, 1998, to February 29, 2020, were included. We collected data on age, index cytology result, year of CIN2 diagnosis, region of residence, civil status, HPV vaccination status, and socioeconomic position indicators. The variables were tabulated overall and by management group (active surveillance vs. LLETZ). To evaluate time trends, we used joinpoint regression to calculate the annual percentage change (APC), including 95% confidence intervals (CI). Results: Of the 27 536 women with CIN2 included, 12 500 (45.4%) underwent active surveillance, and 15 036 (54.6%) underwent a LLETZ. Women undergoing active surveillance were younger, more often HPV‐vaccinated, and more likely to have a normal/low‐grade index cytology result than women undergoing LLETZ. Socioeconomic position indicators did not differ. Over time, the proportion of women undergoing active surveillance increased from 21.7% in 2004 to 73.6% in 2019 (APC 9.7, 95% CI 8.1–11.4). The proportion of women undergoing active surveillance aged <30 declined over time (APC −2.2, 95% CI −2.9 to −1.5). The proportion of women with normal/low‐grade index cytology increased slightly to 51.6% in 2019 (APC 0.8, 95% CI 0.4–1.3). Conclusions: The use of active surveillance for CIN2 has increased over the past two decades in Denmark. Observed differences in characteristics between women undergoing active surveillance vs LLETZ are likely related to indications for clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Synchronous Epidermodysplasia Verruciformis and Intraepithelial Lesion of the Vulva Is Caused by Coinfection With Alpha-Human Papillomavirus and Beta-Human Papillomavirus Genotypes and Facilitated by Mutations in Cell-Mediated Immunity Genes.
- Author
-
Ribeiro, Renan Ribeiro, Sung, C. James, and Quddus, M. Ruhul
- Subjects
- *
VULVAR diseases , *CERVICAL intraepithelial neoplasia , *PAPILLOMAVIRUS diseases , *IMMUNOLOGICAL tolerance , *GENETIC markers , *POLYMERASE chain reaction , *RETROSPECTIVE studies , *IMMUNOHISTOCHEMISTRY , *BIOINFORMATICS , *KERATINOCYTES , *MEDICAL records , *ACQUISITION of data , *GENITAL warts , *GENETIC mutation , *VULVA , *CASE studies , *STAINS & staining (Microscopy) , *MIXED infections , *GENOTYPES , *IMMUNITY , *SEQUENCE analysis - Abstract
Context.--There have been exceedingly few reports of epidermodysplasia verruciformis (EV) or EV-like lesions in the vulva. We describe the first observation of vulvar lesions displaying synchronous EV-like histology and conventional high-grade squamous intraepithelial lesion (HSIL), a finding hitherto unreported in medical literature. Objectives.--To describe this novel vulvar lesion with hybrid features of HSIL and EV, attempt to confirm the hypothesis of coinfection with a and b human papillomavirus (a-HPV and b-HPV) genotypes, and describe relevant underlying genetic mutations. Design.--Cases were retrospectively selected from our institutional archive. Detailed review of clinical information, histologic examination, and whole genome sequencing (WGS) were performed. Results.--Five samples from 4 different patients were included. Three of 4 patients had a history of either iatrogenic immune suppression or prior immune deficiency, and all 3 featured classic HSIL and EV changes within the same lesion. One patient had no history of immune disorders, presented with EV-like changes and multinucleated atypia of the vulva, and was the sole patient without conventional HSIL. By WGS, several uniquely mappable reads pointed toward infection with multiple HPV genotypes, including both a-HPVs and b-HPVs. Mutations in genes implicated in cell-mediated immunity, such as DOCK8, CARMIL2, MST1, and others, were also found. Conclusions.--We provide the first description of vulvar lesions harboring simultaneous HSIL and EV features in the English-language literature, a phenomenon explained by coinfection with a-HPV and b-HPV genotypes. The finding of EV-like changes in a vulvar specimen should prompt assessment of the patient's immune status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Viral vector-based therapeutic HPV vaccines.
- Author
-
Ji, Teng, Liu, Yuchuan, Li, Yutong, Li, Chuanfen, and Han, Yingyan
- Subjects
- *
GENETIC vectors , *HUMAN papillomavirus vaccines , *HUMAN papillomavirus , *VIRAL vaccines , *VACCINE effectiveness , *GENITAL warts - Abstract
Replication-defective viral vector vaccines have several advantages over conventional subunit vaccines, including potent antibody responses, cellular responses critical for eliminating pathogen-infected cells, and the induction of highly immunogenic and durable immune responses without adjuvants. The Human papillomavirus (HPV), a microorganism with over 200 genotypes, plays a crucial role in inducing human tumors, with the majority of HPV-related malignancies expressing HPV proteins. Tumors associated with HPV infection, most of which result from HPV16 infection, include those affecting the cervix, anus, vagina, penis, vulva, and oropharynx. In recent years, the development of therapeutic HPV vaccines utilizing viral vectors for the treatment of premalignant lesions or tumors caused by HPV infection has experienced rapid growth, with numerous research pipelines currently underway. Simultaneously, screening for optimal antigens requires more basic research and more optimized methods. In terms of preclinical research, we present the various models used to assess vaccine efficacy, highlighting their respective advantages and disadvantages. Further, we present current research status of therapeutic vaccines using HPV viral vectors, especially the indications, initial efficacy, combination drugs, etc. In general, this paper summarizes current viral vector therapeutic HPV vaccines in terms of HPV infection, antigen selection, vectors, efficacy evaluation, and progress in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross‐sectional study based on post‐vaccination period 2019 to 2023.
- Author
-
Mo, Bangzhu, Ye, Yuanxin, Yu, Maowen, Tong, Xianli, Cao, Hongmei, Du, Chunmei, Luo, Jiangrong, and Xie, Chunbao
- Subjects
- *
HUMAN papillomavirus , *AGE distribution , *POLYMERASE chain reaction , *PRECANCEROUS conditions , *CARCINOMA in situ , *GENITAL warts - Abstract
Background: Human papillomavirus (HPV) screening and vaccination exert efficacy in controlling the progression of cervical cancer. Thus, examinations into HPV prevalence, age‐stratified specificity, genotype distribution, and their correlation with pathological outcomes can furnish robust evidence for customizing high‐quality population screening and management. Methods: A cohort of 17,923 women attending clinics in the Jintang area, Sichuan, from January 2019 through August 2023 were enrolled in the study. Genotyping of HPV was conducted using real‐time polymerase chain reaction (RT‐PCR). The epidemiology and the relationship between HPV infection and histologic/cytologic abnormalities were subjected to analysis. Results: HPV infection was identified in 4387 women. The outpatient group exhibited a significantly higher HPV infection rate compared to the healthy examination group (26.5% vs. 17.5%, p < 0.05). The distribution of infection rates across different age groups exhibited a U‐shaped pattern, with the highest infection rate in the group ≤20 years of age, succeeded by those >60 years of age. The 31–40 age group demonstrated the lowest prevalence of infection, but upon infection, its prevalence of the precancerous lesion CIN2‐3 reached a maximum of 29.0%, constituting a novel finding. The most prevalent genotype was HPV52, followed by HPV16, 58, 53, 68, and 18. In the cytologic and histologic abnormalities group, the most common types were HPV52, 16, and 58. HPV16 predominantly appeared in high‐grade intraepithelial neoplasia and carcinoma in situ, constituting over 60% of cases. While HPV type 52 was not individually detected in cervical cancer cases. And some other non‐vaccine‐covered HPV subtypes also showed high prevalence in Sichuan. The single infection rates of NH9‐HPV (high‐risk HPV subtypes covered by the non‐nine‐valent vaccine) in CIN2‐3 and cervical cancer patients were 6.5% and 2.6%, respectively. Among them, HPV51, HPV53, HPV59, and HPV35 exhibited a significant preponderance, which even higher than HPV45 and HPV31 covered by the nine‐valent vaccine types. And in NL9‐HPV (low‐risk HPV subtypes covered by the non‐nine‐valent vaccine), HPV42 accounted for the highest percentage in CIN2‐3. A similar decreasing trend was observed in annual infection rates in the healthy examination population and in the 31–40 and 51–60 age groups, while the ≤20 age group showed an increase. Regarding type‐specificity, HPV16 and HPV58 exhibited the most rapid declines. Conclusion: This study furnishes the latest insights into the characteristics of HPV infection rate, age distribution, and genotype prevalence in Sichuan. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9–17 years in China: a cross-sectional study.
- Author
-
Lin, Zian, Chen, Siyu, Su, Lixian, Liao, Yuxue, Chen, Hongbiao, Hu, Zhiqing, Chen, Zhuolin, Fang, Yuan, Liang, Xue, Chen, Jianan, Luo, Biyun, Wu, Chuanan, and Wang, Zixin
- Subjects
- *
HUMAN papillomavirus vaccines , *VACCINE refusal , *VACCINATION status , *MEDICAL communication , *LOGISTIC regression analysis , *GENITAL warts - Abstract
Background: Mothers play a crucial role in influencing their daughters' HPV vaccination decisions. Addressing barriers to receiving HPV vaccination among mothers of girls may achieve two goals in one strike: increasing vaccination coverage among both mothers and their daughters. This study aims to examine the HPV vaccination uptake and its determinants among mothers of girls in China at both the individual and interpersonal levels. Methods: From July to October 2023, a cross-sectional online study was conducted to investigate HPV vaccine refusal for daughters aged 9–17 years among 11,678 mothers in Shenzhen, China. A randomized selection method was employed, targeting 11 primary schools and 13 secondary schools in Shenzhen. The research team invited mothers of girls to participate in an anonymous online survey. Multilevel logistic regression models (level 1: schools; level 2: individual participants) were employed to analyze the data. Results: Among 11,678 mothers, 41.1% self-reported receiving at least one dose of HPV vaccination. Through multilevel logistic regression analysis, eight items measuring illness representations of HPV, which refers to how people think about HPV, were associated with higher HPV vaccination uptake (AOR: 1.02–1.14). These items included identity (identifying symptoms of HPV), timeline (whether HPV is acute/chronic), negative consequences, personal and treatment control (whether HPV is under volitional control), concern, negative emotions, and coherence (overall understanding of HPV). In addition, participants refusing HPV vaccines for the index daughters (AOR: 0.82, 95%CI: 0.76, 0.89) had lower vaccine uptake. Perceived more difficulties in accessing the 9-valent vaccines (AOR: 1.06, 95%CI: 1.04, 1.08) and more satisfaction with vaccine-related promotional materials (AOR: 1.50, 95%CI: 1.46, 1.54) at the individual level were associated with higher vaccine uptake. At the interpersonal factors, higher frequency of exposure to testimonials given by others about HPV vaccination on social media (AOR: 1.19, 95%CI: 1.14, 1.25) and thoughtful consideration of the veracity of the information (AOR: 1.11, 95%CI: 1.07, 1.16) were correlated with higher HPV vaccination uptake. Conclusions: These findings offer essential implications for modifying HPV disease perceptions, addressing difficulties in accessing the 9-valent HPV vaccines, and enhancing health communication needs to improve HPV vaccine uptake among mothers of girls. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Implementation of WHO guidelines for cervical cancer screening, diagnosis and treatment: knowledge and perceptions of health providers from Argentina.
- Author
-
Arrossi, Silvina, Straw, Cecilia, Sanchez Antelo, Victoria, Paolino, Melisa, Baena, Armando, Forestier, Mathilde, Rol, Maryluz, and Almonte, Maribel
- Subjects
- *
MEDICAL societies , *EARLY detection of cancer , *CERVICAL cancer , *DISEASE eradication , *EMPLOYEE training , *GENITAL warts - Abstract
Background: The 2021 World Health Organization (WHO) guidelines on cervical cancer screening and treatment provide countries with evidence-based recommendations to accelerate disease elimination. However, evidence shows that health providers' adherence to screening guidelines is low. We conducted a study in Argentina to analyze health providers' knowledge and perceptions regarding the 2021 WHO Guidelines. Methods: A qualitative study was conducted based on individual, semi-structured interviews with health providers specializing in gynecology (n = 15). The themes explored were selected and analyzed using domains and constructs of the Consolidated Framework for Implementation Research. Results: Although health providers perceive WHO as a reliable institution, they do not know the 2021 guidelines, its supporting evidence, and its elaboration process. Their clinical practice is mainly guided by local recommendations developed by national professional medical associations (PMAs). For interviewees, WHO guidelines should be disseminated through health authorities and national PMAs, mainly through in-service training. Health providers had a positive assessment regarding WHO Recommendation 1 (screen, triage, and treatment for women aged 30 + with HPV-testing every 5 to 10 years) and perceived a favorable climate for its implementation. HPV-testing followed by triage was considered a low-complexity practice, enabling a better detection of HPV, a better selection of the patients who will need diagnosis and treatment, and a more efficient use of health system resources. However, they suggested adapting this recommendation by removing screening interval beyond 5 years. WHO Recommendation 2 (screen-and-treat approach with HPV-testing for women aged 30 + every 5 to 10 years) was predominantly rejected by interviewees, was considered an algorithm that did not respond to women's needs, and was not adequate for the Argentinean context. Regarding the HPV-test modality, clinician-collected tests were the preferred mode. Health providers considered that HPV self-collection should be used primarily among socially vulnerable women to increase screening coverage. Conclusion: WHO guidelines should be widely disseminated among health providers, especially in settings that could benefit from a screen-and-treat approach. Identifying areas of partnership and collaboration with PMAs in implementing WHO guidelines is essential. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Impact of high - risk HPV infections on pregnancy outcomes and vaginal microenvironment.
- Author
-
LI Yaling, NIU Gang, and WANG Wei
- Subjects
- *
PREGNANCY outcomes , *BACTERIAL vaginitis , *FETAL growth retardation , *GENITAL warts , *GENITALIA , *MULTIPLE regression analysis , *MISCARRIAGE - Abstract
Objective To explore the impact of HR-HPV infection on pregnancy outcomes and vaginal microbiota. Methods 128 pregnant women who underwent prenatal examinations at Mingshan Branch of the First Affiliated Hospital of Chengdu Medical College were selected as the research subjects. Both vaginal microbiota and HR-HPV testing were conducted, and single factor analysis and multiple linear regression analysis were used to identify the relevant factors of HR-HPV infection in pregnant women. The impact of HR-HPV infection on pregnancy outcomes and vaginal microbiota was studied. Results Among the 49 cases in the infection group, 30 cases contracted with type 16 HPV, accounting for 61.22%, 13 type 18 HPV, accounting for 26.53%, and 1 type 31, 33, 51, 52, 53, and 58, respectively. Univariate analysis showed that HR-HPV infections were significantly correlated with age of first sexual activity, condom use, number of sexual partners, reproductive tract inflammation, and smoking history (P < 0.05). Multivariate analysis showed that age of first sexual activity ≤ 20 years, concurrent reproductive tract inflammation, multiple sexual partners, and smoking history were independent risk factors for HR-HPV infection, while condom use was an independent protective factor for HR-HPV infection. There were significant differences in the number of lactobacilli, candida infections, and vaginal cleanliness between the two groups (P < 0.05). The incidence of spontaneous abortion and fetal growth restriction in the HR-HPV-infected group was significantly higher than that in the HR-HPV-uninfected group (P < 0.05). Conclusions Pregnant women with HR-HPV infections are closely related to factors such as premature sexual conduct, number of sexual partners, reproductive tract inflammation, and smoking. Infections with HR-HPV during pregnancy can cause changes in the vaginal microenvironment and lead to adverse pregnancy outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Prevalence of herpesviruses in Yanomami indigenous people and its relationship with Heck's disease.
- Author
-
Boaventura, Richardson Mondego, Kussaba, Sergio Takashi, Roman‐Torres, Caio Vinicius G., Kim, Yeon Jung, Zerbinati, Rodrigo Merlin, Braz‐Silva, Paulo Henrique, and Pallos, Debora
- Subjects
- *
HUMAN herpesvirus 1 , *BURKITT'S lymphoma , *HUMAN papillomavirus , *SMOOTH muscle tumors , *KAPOSI'S sarcoma , *GENITAL warts - Abstract
This article explores the prevalence of herpesviruses among the Yanomami indigenous people and its connection to Heck's disease. The study collected saliva samples from 81 individuals from the Yanomami ethnic group and analyzed them for human herpesviruses. The results revealed that several individuals tested positive for various herpesviruses, including HSV-1, EBV, CMV, HHV-6, HHV-7, and HHV-8. The study also found a significant correlation between the presence of Heck's disease and HHV-6 and HSV-1. These findings emphasize the importance of understanding the impact of viruses on indigenous populations and their unique manifestations. The study further examined the prevalence of herpesviruses among the Yanomami indigenous people and its association with Heck's disease. The results indicated that there was no significant difference in the presence of lesions during childhood compared to adolescence and adulthood. However, the disease typically begins before the age of 20 and spontaneously regresses over time. The study also discovered a rare connection between the development of Heck's disease and the presence of EBV, likely due to immunosuppression. Additionally, there was an association between Heck's disease and HSV-1, which is not commonly reported in the literature. This research underscores the need for greater understanding of how these microorganisms behave in indigenous populations and the development of public health policies to address the oral and periodontal conditions of indigenous people. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
13. The relationship between HPV testing attitudes and beliefs, knowledge, and vaccination attitudes: A cross‐sectional study.
- Author
-
Küçükkaya, Burcu, Cangöl Sögüt, Seda, and Cangöl, Eda
- Subjects
- *
SOCIAL media , *HEALTH attitudes , *CONSCIOUSNESS raising , *HUMAN papillomavirus , *HUMAN papillomavirus vaccines , *GENITAL warts - Abstract
Objective Design Sample Measurements Results Conclusion This study aims to examine the relationship between human papillomavirus (HPV) testing attitudes and beliefs, knowledge, and vaccination attitudes.This study was a cross‐sectional design.This study was conducted between March 15, 2024, and June 2, 2024, through social media platforms such as Facebook, Instagram, Twitter, and Telegram, by sharing on forum pages, and involved 674 women who volunteered to participate.The research data were collected using the “health belief model scale regarding HPV infection and vaccination (HBMS‐HPVV)” and the “HPV Testing Attitudes and Beliefs Scale (HTABS),” which were developed by the researchers through a literature review.The average age of the women participating in the study was 46.59 ± 11.15 years; 81.5% were married, 57.6% had no knowledge about cervical cancer, and 62.2% had no knowledge about the HPV vaccine, a protective vaccine against cervical cancer. The average scores for the subdimensions of severity, barriers, benefits, and susceptibility of the HBMS‐HPVV were 3.19 ± 0.60, 2.96 ± 1.22, 2.29 ± 1.40, and 3.92 ± 0.49, respectively. The average scores for the subdimensions of personal barriers, social norms, confidence, and worries of the HTABS were 31.14 ± 19.27, 7.57 ± 4.47, 30.03 ± 7.18, and 11.91 ± 2.52, respectively. A statistically significant positive relationship was found between all HBMS‐HPVV subdimensions and the HTABS subdimensions (
p < 0.001).The study found that as the perceived severity increases, the perceived benefits, susceptibility, and confidence increase, while the perceived barriers, personal barriers, social norms, and worries decrease. Based on these results, it is recommended that women's health nurses provide education and seminars to raise awareness about cervical cancer, early screening and diagnosis programs, and the HPV vaccine. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer.
- Author
-
Beaussire-Trouvay, Ludivine, Duhamel, Orianne, Perdrix, Anne, Lévêque, Emilie, Vion, Roman, Rovelet-Lecrux, Anne, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric, Crouzet, Agathe, Leheurteur, Marianne, and Clatot, Florian
- Subjects
CIRCULATING tumor DNA ,CURATIVE medicine ,HUMAN papillomavirus ,PROGNOSIS ,CERVICAL cancer ,SQUAMOUS cell carcinoma ,END of treatment ,GENITAL warts - Abstract
Background: Cervical cancers are mainly caused by an oncogenic HPV. For locally advanced stages, the standard treatment is radio-chemotherapy (RTCT) followed by brachytherapy. Nevertheless, the prognosis remains highly heterogeneous between patients. Objective: We investigated the prognostic value of HPV circulating tumor DNA (ctDNA) in locally advanced cervical cancers alongside that of Squamous Cell Carcinoma Antigen (SCC-A). Methods: This single-center retrospective study included patients treated in curative intent for an IB3 to IVA squamous cell cervical cancer. Quantification of HPV ctDNA in serum collected at diagnosis was performed using a multiplex digital PCR assay for the simultaneous detection of 8 HPV genotypes. Results: Among the 97 patients included, 76 patients (78.4%) were treated by RTCT, followed by brachytherapy for 57 patients (60%). HPV ctDNA was detected in 59/97 patients at diagnosis (60.8%). This detection was associated with lymph node invasion (p=0.04) but not with tumor stage. A high level of SCC-A at diagnosis was associated with tumor stage (p=0.008) and lymph node invasion (p=0.012). In univariate analysis, better disease-free survival (DFS) was associated with optimal RTCT regimen (p=0.002), exposure to brachytherapy (p=0.0001) and a low SCC-A at diagnosis (continuous analysis, p=0.002). Exploratory analysis revealed that 3/3 patients (100%) whose HPV ctDNA was still detectable at the end of treatment relapsed, while 6/22 patients (27.3%) whose HPV ctDNA was negative at the end of treatment relapsed. Conclusion: HPV ctDNA detection at diagnosis of locally advanced cervical squamous cell carcinomas is frequent and related to node invasion, but not to DFS. The prognostic value of HPV ctDNA detection after treatment warrants specific studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Association between human papillomavirus and preterm delivery: A systematic review and meta‐analysis.
- Author
-
Kovács, Dénes, Szabó, Anett, Hegyi, Péter, Ács, Nándor, Keszthelyi, Márton, Sára, Levente, Csirzó, Ádám, Mátrai, Péter, Munnoch, Krisztina, Nagy, Rita, and Bánhidy, Ferenc
- Subjects
- *
HUMAN papillomavirus , *PREMATURE labor , *GENITAL warts , *SEXUALLY transmitted diseases , *PREGNANCY outcomes , *MISCARRIAGE - Abstract
Introduction Material and Methods Results Conclusions The lifetime prevalence of human papillomavirus infection (HPV) is estimated to be around 80% and it is the most common sexually transmitted infection. Despite being well known for its oncologic relevance, it has been associated with adverse pregnancy outcomes, though available evidence is contradicting. Previous meta‐analyses involved articles which based HPV infection on Pap smear results, leading to a significant source of bias. Therefore, we aimed to assess the burden of genetically proven HPV infection on adverse pregnancy outcomes.In our meta‐analysis, pregnant women tested for HPV DNA were only considered eligible. We conducted a systematic search in three major databases (PubMed, Embase, and CENTRAL) on September 22, 2023. Cohort, cross‐sectional, and case‐control studies were eligible for the analysis. The exposed group consisted of HPV‐infected patients. We assessed the odds ratios (OR) with a confidence interval (CI) of 95%. In order to reduce the heterogeneity, we performed subgroup analyses based on different strains (high risk HPV, HPV 16/18, study design). The study was prospectively registered on PROSPERO (CRD42022370228).Our study involved 14 articles with 7008 women. A significant association was found between preterm delivery and HPV infection (OR: 1.94, CI: 1.31–2.87). No significant association was found when separately examining high‐risk HPV‐infected women (OR: 1.94, CI: 0.82–4.59), and HPV 16 or 18‐infected women (OR: 2.08, CI: 0.50–8.63) in terms of preterm delivery. No significant association was found between spontaneous abortion and HPV infection (OR: 1.02, CI: 0.16–6.31).Our analysis indicates an association between HPV infection and preterm delivery. It is imperative that future studies consider confounding variables more comprehensively. Additionally, the global implementation of HPV vaccination programs holds significance not only in oncology but also in obstetrics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. High silent prevalence of human herpesvirus 1 (HSV-1) infection affecting the indigenous reservation of the municipality of Dourados, Central-West Brazil.
- Author
-
de Oliveira Bonfim, Flávia Freitas, Villar, Livia Melo, Croda, Julio, Pereira, Jéssica Gonçalves, Guimarães, Ana Carolina Silva, da Silva, Solange Rodrigues, Maymone Gonçalves, Crhistinne Cavalheiro, Leonardo, Lucas Fernando Tinoco, de Rezende Romeira, Grazielli Rocha, Cesar, Gabriela Alves, Weis-Torres, Sabrina, de Oliveira Landgraf de Castro, Vivianne, Horta, Marco Aurélio, Simionatto, Simone, Motta-Castro, Ana Rita Coimbra, and de Paula, Vanessa Salete
- Subjects
- *
HUMAN herpesvirus 1 , *INDIGENOUS peoples of South America , *INDIGENOUS peoples , *NEONATAL infections , *GENITAL warts - Abstract
Background: The indigenous population located in the central region of Brazil, is the second largest in terms of population size in the country. The Indigenous Reserve of Dourados has risk factors that increase the vulnerability of the indigenous population to infectious diseases, especially Human alphaherpesvirus (HSV-1), a neglected disease with high prevalence in priority populations in developing countries. The virus can also cause many more severe diseases, including widespread neonatal infections, herpetic keratitis, and herpes encephalitis, which can be fatal if left untreated. We estimated the prevalence of anti-HSV-1 antibodies and correlated it with the demographic and behavioral characteristics of the Indigenous population of the Jaguapirú and Bororó villages (Dourados, Mato Grosso do Sul (MS), Brazil). Methods: Our approach was cross-sectional. From March 2017 to November 2018. Using anti-HSV-1 (Gg1) IgM and anti-HSV-1 (gG1) IgG Euroimmun and the detection and quantification of HSV-1 viral load in plasma samples, through real-time PCR. The maps were constructed using QGIS and the statistical analyses using R Studio software. Results: A total of 1138 individuals (> 18 years old) were enrolled. The prevalence of anti-HSV-1 IgM and IgG were 20% and 97.5%, respectively. The prevalence of anti-HSV-1 antibodies for IgG was higher in both sexes. Anti-HSV-1 IgM antibodies were present in 17.1%, 21.2%, 12.5%, and 22% of the participants with urinary problems, genital wounds, genital warts, and urethral discharge, respectively. Real-time PCR was used for confirmatory testing; HSV-1 DNA was detected in 25.6% (54/211) of anti-HSV1 IgM-positive samples. Viral loads ranged from 5.99E + 02 to 3.36E + 13. Conclusions: The seroprevalence of HSV-1 IgM and detection of HSV-1 DNA in the Indigenous population confirmed high silent prevalence. Furthermore, the seroprevalence of HSV-1 in the Indigenous population was higher than that reported in the general adult Brazilian population. Various socioeconomic factors, drug use, and health and sexual behaviors could contribute to the facilitation of HSV-1 transmission in the Indigenous population. Our results may help develop culturally appropriate intervention programs that eliminate health access barriers and improve the implementation of public health policies aimed at promoting information regarding the prevention, treatment, and control of HSV-1 infection in Brazilian Indigenous populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.
- Author
-
Ladwa, Rahul, Chandra, Janin, Wai-Ping Woo, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Yan Xu, Panizza, Benedict, Frazer, Ian, and Porceddu, Sandro V.
- Subjects
HUMAN papillomavirus vaccines ,SQUAMOUS cell carcinoma ,HUMAN papillomavirus ,GENITAL warts ,DNA vaccines ,VACCINE effectiveness - Abstract
Background: Programmed cell death ligand 1 (PD-L1) inhibitors have limited efficacy as monotherapy in patients with recurrent/metastatic (R/M) Human Papilloma Virus (HPV) oropharyngeal squamous cell carcinoma (OPSCC). A phase I study of the therapeutic HPV-16 DNA vaccine AMV002 in curatively treated patients with OPSCC demonstrated a measurable immune response against HPV while being associated with high safety and tolerability. This prospective phase Ib single centre pilot study aims to test the safety and tolerability of combined PD-L1 inhibitor, Durvalumab, with AMV002 in 12 patients with recurrent OPSCC. Methods: Participants had evidence of R/M HPV-associated OPSCC. They received three intradermal administrations of AMV002 with Durvalumab followed by Durvalumab maintenance. Safety and tolerability data was the primary endpoint. The study was conducted with ethical approval (HREC/2018/QMS/47293) in Brisbane, Australia. Findings: The most common adverse event (AE) related to vaccine administration was erythema at the injection site. There were no grade 3 or 4 vaccine related AEs. There was one presumed immune-related grade 3 elevation in lipase secondary to Durvalumab with no intervention required. No patient ceased study due to treatment-related AEs. At week 16, objective response rate was 8% (N=1) and disease control rate was 17% (N=2). At a median follow up of 25.6 (20.0-26.6) months there was one long term complete response while all other participants developed progressive disease. Of the 11 evaluated patients, 9, (82%) had E6 and/or E7-specific T cell responses to the vaccine. Conclusion: The combination of AMV002 therapeutic HPV-16 vaccine and Durvalumab was found to be safe and well tolerated with no increased safety signals generated. T cell responses to vaccine were observed but further work will be required to improve efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Questionnaire survey on cervical cancer screening and HPV awareness among patients at a local cancer center in Japan.
- Author
-
Nakamura, Kazuto, Kigure, Keiko, Nishimura, Toshio, and Yamashita, Soichi
- Subjects
- *
GENITAL warts , *CERVICAL cancer , *EARLY detection of cancer , *HUMAN papillomavirus , *CANCER patients , *EPIDEMIOLOGY - Abstract
Background: The incidence of cervical intraepithelial neoplasia is increasing in Japan. Although human papillomavirus (HPV) vaccination and cancer screening are crucial in preventing cancer-related mortality, the cervical cancer screening rate in Japan was only approximately 43.6% in 2022. This study aimed to conduct an epidemiological analysis of cervical cancer by collecting data from individual patients. Methods: A questionnaire survey was administered to patients who visited our hospital between January 2017 and July 2023 owing to abnormal cervical cytological findings or a cancer diagnosis. Patients answered questions regarding their history of cervical cancer screening as well as their knowledge of HPV and cervical cancer. Results: During the study period, 471 patients participated in the survey, with 35 declining to participate. Patients with Stage 1b1–4b primarily sought medical attention due to self-reported symptoms (P < 0.001); however, they were less likely to have undergone cervical cancer screening (P < 0.001). Additionally, older patients were less likely to be aware of the association of HPV with cervical and other cancers. Notably, 28 of the 129 patients with stage 1b1–4b cancer underwent cervical cancer screening within 2 years. The tumor location within the endocervical canal emerged as a significant factor contributing to the difficulty for an accurate diagnosis of precancerous or cervical cancer during cervical screening. Furthermore, non- squamous cell carcinoma (SCC) histology was another possible factor. Conclusions: Our findings suggest the need to widely disseminate information regarding the significance of cancer screening to increase cancer screening rates. Moreover, establishing strategies for improving the accuracy of detecting lesions during screening for non-SCC and endocervical canal tumors is crucial. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. HPV Infections—Classification, Pathogenesis, and Potential New Therapies.
- Author
-
Mlynarczyk-Bonikowska, Beata and Rudnicka, Lidia
- Subjects
- *
HUMAN papillomavirus , *PAPILLOMAVIRUSES , *GENITAL warts , *VIRAL proteins , *PATHOGENESIS , *VIRAL replication , *ARACHNOID cysts - Abstract
To date, more than 400 types of human papillomavirus (HPV) have been identified. Despite the creation of effective prophylactic vaccines against the most common genital HPVs, the viruses remain among the most prevalent pathogens found in humans. According to WHO data, they are the cause of 5% of all cancers. Even more frequent are persistent and recurrent benign lesions such as genital and common warts. HPVs are resistant to many disinfectants and relatively unsusceptible to external conditions. There is still no drug available to inhibit viral replication, and treatment is based on removing lesions or stimulating the host immune system. This paper presents the systematics of HPV and the differences in HPV structure between different genetic types, lineages, and sublineages, based on the literature and GenBank data. We also present the pathogenesis of diseases caused by HPV, with a special focus on the role played by E6, E7, and other viral proteins in the development of benign and cancerous lesions. We discuss further prospects for the treatment of HPV infections, including, among others, substances that block the entry of HPV into cells, inhibitors of viral early proteins, and some substances of plant origin that inhibit viral replication, as well as new possibilities for therapeutic vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Exploring the Impact of Knowledge about the Human Papillomavirus and Its Vaccine on Perceived Benefits and Barriers to Human Papillomavirus Vaccination among Adults in the Western Region of Saudi Arabia.
- Author
-
Alsulami, Fahad T.
- Subjects
PAPILLOMAVIRUS diseases ,HEALTH literacy ,HEALTH services accessibility ,CROSS-sectional method ,RISK assessment ,SCALE analysis (Psychology) ,CERVIX uteri tumors ,MOUTH tumors ,CRONBACH'S alpha ,T-test (Statistics) ,STATISTICAL hypothesis testing ,VACCINATION ,QUESTIONNAIRES ,RESEARCH evaluation ,MULTIPLE regression analysis ,HUMAN papillomavirus vaccines ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,RELATIVE medical risk ,ATTITUDE (Psychology) ,SURVEYS ,VACCINATION coverage ,VACCINATION promotion ,TEST validity ,ONE-way analysis of variance ,GENITAL warts ,DATA analysis software ,SOCIODEMOGRAPHIC factors ,PATIENTS' attitudes ,DISEASE risk factors ,DISEASE complications ,ADULTS - Abstract
Objective: To evaluate knowledge about HPV and its vaccine, additionally, to examine the effect of knowledge about HPV and its vaccine on perceived benefits and barriers to HPV vaccination among individuals in the western region of Saudi Arabia. Methods: A cross-sectional design was employed in the western region of Saudi Arabia through a self-administered web-based survey. The survey assessed knowledge, perceived benefits, and perceived barriers to HPV vaccination. Results: A total of 1149 eligible participants completed the survey. Participants exhibited limited knowledge of HPV and its vaccine, with an average total score of 4.76 out of 15. Over 80% of participants were unaware that HPV may not show symptoms, cannot lead to HIV, and is not treatable with antibiotics. Over half were unaware that HPV can cause cervical cancer, oral cancer, or genital warts. Unmarried and graduate-educated participants demonstrated greater knowledge. Perceived benefits were positively associated with knowledge levels, while perceived barriers were negatively associated with knowledge levels after controlling for other variables. Conclusions: This study highlights the need for education and healthcare efforts to raise knowledge about HPV and its vaccine in the western region of Saudi Arabia. Also, this study indicated that enhanced knowledge boosts positive attitudes towards HPV vaccination, while reducing perceived barriers, thereby increasing vaccination rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Human papillomavirus (HPV) vaccination in Japan.
- Author
-
Miyagi, Etsuko
- Subjects
- *
GENITAL warts , *HUMAN papillomavirus , *HUMAN papillomavirus vaccines , *SOMATOFORM disorders , *VACCINATION , *CONSCIOUSNESS raising - Abstract
Aim Methods Results Conclusions To review the status of human papillomavirus (HPV) vaccination in Japan from inception to the present, focusing on past and current challenges.Published articles and website content related to HPV vaccination were reviewed.The Ministry of Health, Labor and Welfare suspended proactive recommendations for HPV vaccination in June 2013 following repeated media reports of girls experiencing adverse events, including chronic pain and walking disturbances, after receiving the HPV vaccine. Despite later recognition of these symptoms as a functional somatic syndrome, HPV vaccine coverage of target girls aged 12 to 16 years in the National Immunization Program (NIP) rapidly decreased to near zero. This suspension of the proactive HPV vaccination recommendation ceased in fiscal year (f‐year) 2022, initiating a 3‐year catch‐up free HPV vaccination period from April 2022 to March 2025 for women born from f‐years 1997 to 2005. These drastic changes were driven by established evidence of the effectiveness and safety of HPV vaccines reported from both Japan and other countries, and a nine‐valent HPV vaccine has been included in the NIP since f‐year 2023. However, the estimated HPV vaccination rate in the NIP remains low at ≤30%.To regain high coverage of HPV vaccination in Japan, it is essential that government, industry, and academic society work together to raise awareness and educate Japanese people about cervical cancer prevention and HPV‐related diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. A transversal cross-sectional study of factors related to HPV vaccination status and cancer screening participation among French women aged 25–40.
- Author
-
Serman, Fanny, Lisembard, Gabrielle, Sahraoui, Maxence, Berkhout, Christophe, Rochoy, Michaël, Haro, Anthony, and Calafiore, Matthieu
- Subjects
- *
GENITAL warts , *VACCINATION status , *HUMAN papillomavirus vaccines , *EARLY detection of cancer , *CANCER vaccines , *HUMAN papillomavirus , *CANCER education , *ANTI-vaccination movement - Abstract
Background: In 2020, uterine cervical cancer (UCC) was the 12th most common cancer among women in France and the 4th worldwide. French health authorities wanted to increase Human Papilloma Virus (HPV) vaccination and screening rates. There were still many barriers to these measures among young women, their families, and health professionals and teachers. Between 2014 and 2019, international studies found inconsistent effects of HPV vaccination on UCC screening. In 2022, a survey was conducted among women aged 25 to 40 in the Nord-Pas-de-Calais region to assess participation 1) in HPV vaccination and its barriers, 2) in UCC screening as a function of HPV vaccination status. Methods: Data were collected using an anonymous online questionnaire distributed by QR code in 80 general practices randomly selected in the Nord-Pas-de-Calais region between January and June 2022. Results were analyzed bivariately using the Chi2 test, multivariately when numbers allowed, and in age subgroups (sensitivity analysis). Results: 407 complete questionnaires (for 602 participating women) were analyzed. In our sample, 41% of women aged 25 to 40 in the Nord-Pas-de-Calais region were vaccinated against HPV viruses in 2022. The risk factors for non-vaccination, after multivariable adjustment, were: the periods of eligibility for vaccination in the early days of French vaccination (2007–2012: odds ratio OR = 0.04 [95% CI, 0.02–0.09]; 2012–2017: OR = 0.5 [0.3–0.8]), information received from non-medical sources (OR = 0.3 [0.2–0.6]), and absence of information about vaccination (OR = 0.12 [0.05–0.27]). In our sample, 90% of women were screened for UCC. In bivariate analysis, women at risk of not being screened were those who were youngest, had been vaccinated against HPV, were not heterosexual, lived alone, had gynecological follow-up by their general practitioner, and did not have regular gynecological follow-up. Sensitivity analysis showed that the only risk factor significantly correlated with non-screening regardless of age group was lack of regular gynecological follow-up. Conclusions: Participation in HPV vaccination and UCC screening is improved by medical education and gynecological follow-up. This multicenter study, limited by the relative youth of vaccination in France, should be repeated after 2037 to assess the possible effect of vaccination on screening. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Clinical efficacy of a new therapeutic option for lower genital tract lesions: 5-ALA photodynamic therapy.
- Author
-
Liu, Yingzhen, Medlege, Hekabakila-Banzouzi, Kang, Yanan, Wu, Lisha, Yang, Wenqing, Zhang, Yu, and Tian, Yan
- Subjects
- *
PHOTODYNAMIC therapy , *GENITALIA , *HUMAN papillomavirus , *POSTMENOPAUSE , *GENITAL warts , *GENITALIA infections - Abstract
The study utilized 5-ALA-PDT to treat patients with CIN or VaIN and assessed their clinical response, HPV clearance, and influencing factors after photodynamic therapy (PDT). This study involved 56 patients who received 5-ALA-PDT in a single center from May 2020 to March 2022, including 12 patients with CIN, 30 patients with VaIN, and 14 patients with both CIN and VaIN. Follow-up were conducted within 6 and 12 months after treatment to evaluate the clinical effectiveness of PDT. The assessment criteria included histological response (ER, elimination rate, RR, regression rate) and HPV clearance. Additionally, factors that could potentially influence the outcomes were analyzed. After PDT, the histological response showed an ER of 48.2% (27/56) and a RR of 80.4% (45/56) within 6 months of follow-up. The elimination rate increased to 69.6% (39/56) within 12 months, along with a regression rate of 82.1% (46/56). The rates of HPV clearance were observed to be 37.5% (21/56) and 44.6% (25/56) within 6 and 12 months, respectively. The study also revealed that HPV clearance significantly influenced histologic elimination within 6 months (p < 0.001) and histologic regression within 12 months (p < 0.01). Furthermore, premenopausal women exhibited a higher HPV clearance rate compared to postmenopausal women (61.5% vs. 30.0%, p = 0.036). 5-ALA PDT can be considered as an available option for the treatment of lower genital squamous intraepithelial lesions. The efficacy of its histologic response depends on HPV clearance. Additionally, it has been found that premenopausal women may benefit more from this treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Sexual and reproductive health in young women with ADHD from the view of health care professionals.
- Author
-
Wallin, Karin, Alehagen, Siw, Hanberger, Lena, Lundell, Inger Wallin, and Hultsjö, Sally
- Subjects
- *
MEDICAL personnel , *YOUNG women , *REPRODUCTIVE health , *SEXUALLY transmitted diseases , *WOMEN'S sexual behavior , *IMPOTENCE , *GENITAL warts - Abstract
Background: Sexual risk-taking and struggles in managing romantic relationships may put young women with Attention Deficit Hyperactivity Disorder (ADHD) at risk of sexually transmitted diseases, unplanned pregnancies, and low relational satisfaction. To gain understanding of sexual behaviors and intimate relationships, this study aimed to identify and describe health care professionals' (HCPs) perceptions and experiences of sexual and reproductive health (SRH) in young women with ADHD. Methods: Qualitative interviews were performed with 16 HCPs. Data was analyzed using reflexive thematic analysis. Results: Analysis resulted in the themes Struggling to meet expectations, Sexual risk-taking, and Complex romantic relationships. HCPs' perceptions and experiences indicated that some women were afraid to be judged in clinical meetings when not living up to perceived expectations of sexual behaviors. Lack of impulse control was interpreted by HCPs to result in risk-taking behaviors leading to both negative and positive sexual experiences. Difficulties in assessing intentions of sexual partners were further perceived by HCPs to sometimes lead to sexual regrets or sexual victimization. The HCPs had experience of women wishing for romantic relationships but described these as being complicated by previous experiences, low self-esteem and conflict. ADHD medication and self-knowledge were perceived by HCPs to facilitate the women's relationship quality. Conclusions: This study highlights that, from the perspective of HCPs, self-stigmatization and hesitation to raise issues concerning sexuality with HCPs may pose risks for young women with ADHD. It provides insight into sexual risk-taking behaviors, showing the link to regretted sex and sexual victimization. The study concludes that there is a need for HCPs to understand the influence of stigma concerning ADHD and female sexuality as well as how symptoms and outcomes of living with ADHD may impact SRH in order to promote healthy behaviors and relationships in young women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Comparing the Effect of 20% Zinc Oxide Ointment With 80% Trichloroacetic Acid Solution in the Treatment of Genital Warts: A Single-Blind Randomized Clinical Trial.
- Author
-
Sharami, Rehane Yosefi, Rezaei, Masoumeh, Seyedoshohadaei, Fariba, Rahmani, Khaled, and Bakhshayeshi, Leila Safar
- Subjects
- *
TREATMENT effectiveness , *ZINC oxide , *CLINICAL trials , *GENITAL warts , *ACID solutions , *WARTS - Abstract
Objectives: There are several treatment options for genital warts, but many can cause skin sensitivities or lead to a recurrence of lesions. This study seeks to compare the effectiveness of 20% zinc oxide ointment with 80% trichloroacetic acid (TCA) solution for treating genital warts. Materials and Methods: In this single-blind randomized clinical trial, 88 women with genital warts were divided into two groups of 44. Group A received treatment with zinc oxide, while group B was treated with TCA. Patients were followed up three times, at the end of the fourth, eighth, and twelfth weeks after the start of treatment, to assess the effectiveness of the treatments for genital warts. Results: The number, thickness, and diameter of genital warts decreased significantly in both groups during 12-week period (P=0.0001). However, the reduction in the number, thickness, and diameter of warts was significantly greater in the TCA group compared to the zinc oxide group (P=0.001). After 12 weeks, the TCA group achieved complete clearance of lesions in 84.1% of patients, while the zinc oxide group had a 31.7% clearance rate (P=0.001). Conclusions: Given the significantly higher rate of complete clearance of lesions achieved with TCA compared to zinc oxide, it may be a more effective treatment option and preferable in the management of genital warts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies.
- Author
-
Wei, Jiahui and Wu, Yumei
- Subjects
- *
HYSTERECTOMY , *HUMAN papillomavirus , *TUMORS , *DIAGNOSIS , *PRECANCEROUS conditions , *GENITAL warts - Abstract
Vaginal intraepithelial neoplasia (VaIN), a precancerous lesion associated with human papillomavirus (HPV), impacts women's health and quality of life. However, the natural progression of VaIN after hysterectomy remains uncertain, due to its low incidence. The existing literature predominantly consists of single-center retrospective studies lacking robust evidence-based medicine. The management of VaIN after hysterectomy is diverse and controversial, lacking a consensus on the optimal approach. Therefore, it is imperative to investigate the development of VaIN after hysterectomy, emphasizing the importance of accurate diagnosis and effective management strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. The Role of Neutrophil-Lymphocytes Ratio in the Prognosis of CIN2+ Recurrence after Excisional Treatment.
- Author
-
Dominoni, Mattia, Barcellini, Amelia, Pasquali, Marianna Francesca, De Silvestri, Annalisa, Ferretti, Virginia Valeria, Cesari, Stefania, Fiandrino, Giacomo, Orlandi, Ester, and Gardella, Barbara
- Subjects
- *
BLOOD cell count , *LEUKOCYTE count , *CERVICAL intraepithelial neoplasia , *NEUTROPHIL lymphocyte ratio , *PAP test , *GENITAL warts - Abstract
Objectives: The main risk factor involved in CIN2+ recurrence after treatment is the HPV persistent infection. The dysregulation of the immune system permits only HR-HPVs to become persistent infections, to promote cancer development, and to increase the risk of recurrence after treatment. Therefore, there is a shift to a Th2-type cytokine pattern during the carcinogenesis pathway; for this reason, the neutrophil-lymphocytes ratio (NLR) could be a marker of this immunological change. The study aimed to analyse the predictive role of NLR in the recurrence of high-grade CIN (CIN2+) after excisional treatment in a real-world life setting of patients treated for CIN2+. Design: This study wascross-sectional study. Participants/Materials, Setting, Methods: We examined a retrospective database of 444 patients, who attended the colposcopy service of our department from 2011 to 2020 due to an abnormal screening Pap smear, and we compared the clinical characteristics to NLR performed at the time of diagnosis. All analysed patients were treated according to an established protocol (colposcopy every 6 months for the first 2 years and every year for over 3 years) and HPV-DNA test and cervical biopsy were performed at entry and the end of follow-up. All patients underwent a blood sample examination, including complete white blood cell counts and collecting neutrophil and lymphocyte values expressed as 103/mL. Results: The sensitivity (SE) and specificity (SP) of the NLR cut-off point of 1.34 for the diagnosis of CIN2+ recurrence were 0.76 and 0.67, respectively. We found that CIN2+ recurrences were significantly higher in patients with NLR <1.34 (3.7% vs. 0.6%, p = 0.033) and the 5-year recurrence-free survival was higher in patients with NLR ≥1.34 (97% vs. 93%, p = 0.030). Limitations: Firstly, the retrospective analysis and low incidence of recurrence may limit the conclusions. Second, for the retrospective design of the study, we did not take into consideration the patient's comorbidities and habits (smoking) that may influence the NLR. On the other hand, the median duration of follow-up in our study was 26 months (IQR: 22–31), which fully reflects the incidence of recurrences. Conclusions: It is well known that CIN2+ lesions are sustained by deregulation of the immune system caused by persistent HPV infection, which may lead to cervical cancer. Among the actors underlying dysregulation of immunity, lymphocytes are involved in the permission of persistent infection and for this reason, NRL could be a reliable and cost-effective biomarker in predicting the risk of recurrence, especially for high-grade cervical lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea.
- Author
-
Kyeongmin Kwak and Seung-sik Hwang
- Subjects
- *
HUMAN papillomavirus , *HUMAN papillomavirus vaccines , *VACCINE effectiveness , *CERVICAL cancer , *AGE groups , *GENITAL warts - Abstract
Purpose: This study aimed to evaluate the effectiveness of the national human papillomavirus (HPV) vaccination program of South Korea among its entire female population, particularly among younger age groups. Materials and Methods: We first predicted the incidence of cervical cancer over the next 20 years (2021-2040) using the Nordpred package based on Møller's age-period-cohort model under several scenarios for the national HPV vaccination program. We calculated the potential impact fractions and proportional differences under the current national vaccination programs, and alternative scenarios using the no-vaccination assumption as a reference. Results: We estimated that the current national vaccination program would prevent 4.13% of cervical cancer cases and reduce the age-standardized incidence rate (ASR) by 8.79% in the overall population by 2036-2040. Under the alternative scenario of implementing the nine-valent vaccine, 5.13% of cervical cancer cases could be prevented and the ASR reduced by 10.93% during the same period. In another scenario, expanding the vaccination age to 9-17 years could prevent 10.19% of cervical cancer cases, with the ASR reduced by 18.57% during the same period. When restricted to ages < 40 years, the prevention effect was remarkably greater. We predict that the current national HPV program will reduce its incidence by more than 30% between 2036 and 2040 in women aged < 40 years. Conclusion The effectiveness of the vaccination program in reducing the incidence of cervical cancer was confirmed, with a considerable impact anticipated in younger age groups. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis.
- Author
-
Jin, Fengyi, Vajdic, Claire M, Poynten, I Mary, McGee-Avila, Jennifer K, Castle, Philip E, and Grulich, Andrew E
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *HIV-positive persons , *DISEASE risk factors , *CANCER patients , *AT-risk people , *GENITAL warts , *ANAL cancer - Abstract
Systematic evaluations of cancer risk in people living with HIV or AIDS (PLHIV) and solid organ transplant recipients provide unique insights into the role of the immune system in cancer development. In this systematic review and meta-analysis, we expand previous analyses of cancer risk for these two immunocompromised populations. We considered studies published in English and listed on PubMed or Embase up to July 1, 2022. Studies were eligible for inclusion if they used population-based registries and compared cancer incidence in PLHIV or solid organ transplant recipients with the general population in the same geographical area. We extracted the number of observed site-specific cancers and expected cases and calculated meta-standardised incidence ratios for cancer within PLHIV and solid organ transplant recipients. In solid organ transplant recipients meta-standardised incidence ratios were compared by organ type. This project is registered on PROSPERO, CRD42022366679. 46 studies in PLHIV and 67 in solid organ transplant recipients were included in the analysis. Meta-standardised incidence ratios for cancers associated with human papillomavirus were increased in both populations; the highest meta-standardised incidence ratio in PLHIV was anal cancer (37·28 [95% CI 23·65–58·75], I 2=97·4%), and in solid organ transplant recipients was cutaneous squamous cell carcinoma (45·87 [31·70–66·38], I 2=99·0%). Meta-standardised incidence ratios were significantly increased for most non-HPV viral-infection-related cancers in both populations; the highest standard incidence ratios were for Kaposi sarcoma (PLHIV: 801·52 [95% CI 200·25–3208·13], I 2=100·0%; solid organ transplant recipients: 47·31 [23·09–96·95], I 2=87·7%) and non-Hodgkin lymphoma (32·53 [19·64–53·87], I 2=99·8%; 10·24 [8·48–12·35], I 2=94·9%). Eight types of cancer with no known viral cause showed an increased risk in solid organ transplant recipients only; no cancer type showed increased risk in PLHIV only. Cancer risk was increased for a range of infection-related cancers in both PLHIV and solid organ transplant recipients, but divergent results in these and other cancers have emerged. The cancer risk patterns probably reflect variances in the degree of impaired immunity, exposure to carcinogenic viruses, and perhaps exposure to carcinogenic immunosuppressive agents. US National Cancer Institute, National Institutes of Health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature.
- Author
-
Flach, Susanne, Maniam, Pavithran, Hey, Shi Ying, and Manickavasagam, Jaiganesh
- Subjects
- *
LITERATURE reviews , *HUMAN papillomavirus , *SQUAMOUS cell carcinoma , *GENITAL warts , *METASTASIS , *DRUG target - Abstract
Objectives: About 17% of patients with human papillomavirus (HPV)‐positive head and neck squamous cell carcinoma (HNSCC), which is mainly comprised of oropharyngeal SCC (OPSCC), will experience disease recurrence, which is often considered incurable when manifested at a metastatic and/or recurrent stage. We conducted a critical qualitative systematic review. Our objectives were to provide an overview of the molecular landscape of recurrent/metastatic HPV‐positive HNSCC as well as novel molecular biomarkers. Design: A literature review was conducted to identify studies reporting on the molecular characteristics of recurrent/metastatic HPV‐positive HNSCC, novel molecular biomarkers and treatment options. The reviews of abstracts, full articles, and revision of the included studies, followed by data extraction and quality assessment were performed by three independent assessors. All primary literature, such as retrospective, prospective, and clinical trials as well as basic research studies were considered, and the final search was conducted at the end of February 2023. The level of evidence was rated using the guidelines published by the Oxford Centre for Evidence‐based Medicine and quality was assessed using the Newcastle‐Ottawa Scale criteria. Results and Conclusions: The literature search resulted in the identification of 1991 articles. A total of 181 full articles were screened, and 66 articles were included in this analysis. Several studies reported that recurrent/metastatic HPV‐positive HNSCC had higher rates of TP53 mutation and were genomically similar to HPV‐negative HNSCC. The detection of circulating tumour tissue‐modified HPV DNA (ctHPVDNA) as a specific biomarker has shown promising results for monitoring treatment response and recurrence in the subset of HPV‐positive HNSCC. In addition, evidence for targeted therapy in recurrent/metastatic HPV‐positive HNSCC has emerged, including agents that inhibit overexpressed EGFR. Studies of combination immunotherapy are also underway. Our review outlines the latest evidence on the distinct molecular profiles of recurrent/metastatic HPV‐positive HNSCC as well as the clinical potential of ctHPVDNA testing in routine practice. More controlled and longitudinal studies are needed to identify additional molecular targets and to assess the performance and benefits of novel molecular biomarkers in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP).
- Author
-
Aga, Alfred, Bekteshi, Eliesa, Ajasllari, Guardmond, Kosta, Armida, Vajushi, Emirjona, Kortoci, Rinard, Filauro, Marta, Muka, Taulant, and Peretti, Giorgio
- Subjects
- *
PAPILLOMAVIRUS diseases , *PAPILLOMA , *HUMAN papillomavirus vaccines , *GENITAL warts , *MICROSURGERY , *BEVACIZUMAB , *LARYNGOSCOPY , *INJECTIONS - Abstract
Purpose: Recent approaches for recurrent respiratory papillomatosis including local injection of bevacizumab and HPV vaccination show promise in reducing the need for frequent surgeries. In this study we propose a new combined approach of surgery, intralesional injection of 25 mg bevacizumab and HPV vaccine that can lead to resolution of RRP. Material and methods: Our study involved 5 patients treated with a combination of transoral microsurgery, intralesional injection of 25 mg bevacizumab, and HPV vaccination with Gardasil 9 between April 2020 and May 2023. Standard video laryngoscopy was performed to assess the presence of papilloma and Derkay score was used to assess the severity of disease. Results: All 5 patients completed the study successfully and a complete response was achieved by all. The follow-up ranged from 8 to 45 months. The mean total Derkay score before treatment was 41 (range 25 to 52) and after the combined approach was 0 both anatomically and clinically in all patients. Conclusions: This study demonstrates the effectiveness of a combined treatment approach for RRP involving surgical intervention, intralesional injection of bevacizumab, and HPV vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Coincidence or association: Adult‐onset Still's disease following HPV vaccine.
- Author
-
Ahmed, Muhammad, Husain, Kaab, Husain, Arqam, Syed, Sameer, Haque, Mahfujul Z., and Meysami, Alireza
- Subjects
- *
STILL'S disease , *HUMAN papillomavirus vaccines , *GENITAL warts - Abstract
Key Clinical Message: This case details adult‐onset Still's disease (AOSD) onset post‐human papillomavirus (HPV) vaccination and acute gastroenteritis. The timing of HPV vaccine and vaccine‐autoimmune disease literature may potentially confound the well‐established link between infections and AOSD onset. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Netherton syndrome and papillomatous lesions—Should we perform human papilloma virus vaccination?
- Author
-
Fölster‐Holst, Regina, Pasmans, Suzanne, Volc‐Platzer, Beatrix, Christophers, Enno, and Çetinarslan, Tubanur
- Subjects
- *
HUMAN papillomavirus , *SKIN cancer , *GENITAL warts , *SYNDROMES , *ASTHMA , *VACCINATION , *HUMAN papillomavirus vaccines - Abstract
This document provides a review of the literature on Netherton syndrome (NS), a rare genetic skin disorder. It focuses on the association between papillomatous lesions and skin cancer in NS patients. The most common location for these lesions is the genital area, but they can also occur on other parts of the body. Persistent infection with high-risk HPV types is a major risk factor for developing HPV-induced malignancies. The document also mentions the lack of data on the safety of HPV vaccination in NS patients and the need for further research in this area. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
34. Social capital interventions for human papillomavirus (HPV) immunization and cervical cancer screening: A rapid literature review.
- Author
-
Gillies, Christina, Allen-Scott, Lisa K., Nykiforuk, Candace I. J., Belon, Ana Paula, Kim, Minji Olivia, Lee, Bernice, Nieuwendyk, Laura, Adhikari, Kamala, and Ori, Elaine M.
- Subjects
HUMAN papillomavirus ,EARLY detection of cancer ,LITERATURE reviews ,CERVICAL cancer ,SOCIAL capital ,GENITAL warts - Abstract
Background: Social capital can be used as a conceptual framework to include social context as a predictor of human papillomavirus (HPV) vaccination and cervical cancer screening behaviours. However, the effectiveness of interventions that use social capital as a mechanism to improve uptake of immunization and screening remains elusive. Objective: To synthesize empirical evidence on the impact of social capital interventions on HPV immunization and cervical cancer screening and describe key characteristics of such interventions. Methods: Using a rapid review methodology, a search of literature published between 2012 and 2022 was conducted in four databases. Two researchers assessed the studies according to inclusion criteria in a three-step screening process. Studies were assessed for quality and data concerning social capital and equity components and intervention impact were extracted and analyzed using narrative synthesis. Results: Seven studies met the inclusion criteria. Studies found improved knowledge, beliefs and intentions regarding HPV immunization and cervical cancer screening. None of the studies improved uptake of immunization; however, three studies found postintervention improvements in uptake of cervical cancer screening. All studies either tailored their interventions to meet the needs of specific groups or described results for specific disadvantaged groups. Conclusion: Limited evidence suggests that interventions that consider and reflect local context through social capital may be more likely to increase the uptake of HPV immunization and cervical cancer screening. However, further research must be done to bridge the gap in translating improvements in knowledge and intention into HPV immunization and cervical cancer screening behaviours. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Exploring the Antiviral Potential of Polyphenols against Re-emerging and Emerging Viral Infections: A Comprehensive Review.
- Author
-
Orosco, Fredmoore L. and Dapar, Mark Lloyd G.
- Subjects
SARS-CoV-2 ,INFECTIOUS bursal disease virus ,EPICATECHIN ,CHEMICAL processes ,CERVICAL intraepithelial neoplasia ,ROSMARINIC acid ,HUMAN herpesvirus 1 ,GRAPEFRUIT ,GENITAL warts - Published
- 2024
- Full Text
- View/download PDF
36. A Systematic Review of Human Papillomavirus Vaccination Challenges and Strategies to Enhance Uptake.
- Author
-
Tobaiqy, Mansour and MacLure, Katie
- Subjects
HUMAN papillomavirus vaccines ,MEDICAL personnel ,STUDENT engagement ,VACCINATION coverage ,VACCINATION status ,GENITAL warts - Abstract
Human papillomavirus (HPV) vaccination has revolutionized cervical cancer prevention. Clinical trials confirm that the quadrivalent (HPV types 6, 11, 16, 18) and bivalent (HPV types 16, 18) vaccines effectively prevent HPV infections and cervical neoplasia. The latest HPV vaccine protects against nine virus types responsible for 90% of cervical cancer cases globally. Despite their undoubted effectiveness in reducing morbidity and mortality associated with HPV infections, challenges in vaccine coverage and uptake persist. The current study aimed to identify the primary challenges associated with HPV vaccination, propose effective strategies to improve vaccination uptake, and compile relevant evidence into a comprehensive overview to inform policy and practice. A systematic review protocol, following PRISMA-P and PRISMA guidelines, was established. Articles were sourced from the Web of Science using keywords from a comprehensive review of HPV vaccination challenges and strategies. Studies published between 1 January 2020, and 1 May 2024, including RCTs and observational, qualitative, and cross-sectional studies, were included, while reviews, protocols, and commentaries were excluded. Titles, abstracts, and full texts were screened per PRISMA guidelines. The review identified five key strategies to improve HPV vaccination uptake: parental and school engagement, use of technology and multimedia tools, healthcare providers' role, multicomponent interventions, and targeted interventions for immigrant groups. This review emphasized the need for a multifaceted approach to improving vaccination rates, offering a robust foundation for policy and stakeholder initiatives. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Comparing the Effect of 20% Zinc Oxide Ointment With 80% Trichloroacetic Acid Solution in the Treatment of Genital Warts: A Single-Blind Randomized Clinical Trial
- Author
-
Rehane Yosefi Sharami, Masoumeh Rezaei, Fariba Seyedoshohadaei, Khaled Rahmani, and Leila Safar Bakhshayeshi
- Subjects
genital warts ,trichloroacetic acid ,zinc oxide ,Medicine - Abstract
Objectives: There are several treatment options for genital warts, but many can cause skin sensitivities or lead to a recurrence of lesions. This study seeks to compare the effectiveness of 20% zinc oxide ointment with 80% trichloroacetic acid (TCA) solution for treating genital warts. Materials and Methods: In this single-blind randomized clinical trial, 88 women with genital warts were divided into two groups of 44. Group A received treatment with zinc oxide, while group B was treated with TCA. Patients were followed up three times, at the end of the fourth, eighth, and twelfth weeks after the start of treatment, to assess the effectiveness of the treatments for genital warts. Results: The number, thickness, and diameter of genital warts decreased significantly in both groups during 12-week period (P=0.0001). However, the reduction in the number, thickness, and diameter of warts was significantly greater in the TCA group compared to the zinc oxide group (P=0.001). After 12 weeks, the TCA group achieved complete clearance of lesions in 84.1% of patients, while the zinc oxide group had a 31.7% clearance rate (P=0.001). Conclusions: Given the significantly higher rate of complete clearance of lesions achieved with TCA compared to zinc oxide, it may be a more effective treatment option and preferable in the management of genital warts.
- Published
- 2024
- Full Text
- View/download PDF
38. Natural Products in Controlling and Treatment of Cancers and Genital Warts Caused by Different Viruses
- Author
-
Saha, Supriyo, Mahar, Riya, Pal, Dilipkumar, Mérillon, Jean-Michel, Series Editor, Ramawat, Kishan Gopal, Series Editor, Pavlov, Atanas I., Editorial Board Member, Ekiert, Halina Maria, Editorial Board Member, Aggarwal, Bharat B., Editorial Board Member, Jha, Sumita, Editorial Board Member, Wink, Michael, Editorial Board Member, Waffo-Téguo, Pierre, Editorial Board Member, Riviere, Céline, Editorial Board Member, and Pal, Dilipkumar, editor
- Published
- 2024
- Full Text
- View/download PDF
39. Awareness of cervical cancer risk factors and preventive approaches, and perceived causes of cervical cancer among secondary school girls: a cross-sectional study in Northern Uganda.
- Author
-
Oringtho, Stephen, Mwaka, Amos Deogratius, Orach, Christopher Garimoi, and Wabinga, Henry
- Subjects
HUMAN papillomavirus ,SCHOOLGIRLS ,CERVICAL cancer ,SEXUAL intercourse ,HUMAN papillomavirus vaccines ,GENITAL warts ,INFORMATION needs - Abstract
Background: The majority of women in low- and middle-income countries have low awareness of cervical cancer. This study sought to establish awareness of cervical cancer risk factors and preventive approaches, as well as sources of information and perceived causes of cervical cancer among secondary school girls in northern Uganda. Methods: This was a cross-sectional study conducted in rural northern Uganda. We collected data using an investigator administered pre-tested questionnaire. Analysis was done with STATA version 14.0. Multivariate analyses with logistic regressions models were used to determine magnitudes of association between independent and outcome variables. Odds ratios and accompanying 95% confidence intervals are reported. Statistical significance was considered if the two sided p-value <.05. Results: Most participants (97%; n = 624) had heard of cervical cancer before this study. The most common source of information about cervical cancer was friends (31.1%; n = 194). More than half of the participants (59%; n = 380) had heard about a vaccine that prevents cervical cancer, but only a third (33%; n = 124) had ever received a dose of the vaccine. The majority of participants (89%; n = 550) reported that cervical cancer could be prevented; however only half (52%; n = 290) knew that vaccination of girls aged 9-13 years could prevent cervical cancer. The majority of participants did not recognize the risk factors for cervical cancer; for example, only 15% (n = 98), 7% (n = 45), and 1.4% (n = 9) recognized early onset of sexual intercourse, infection by the human papillomavirus (HPV), and smoking respectively. On adjusting for age, students' class, and religion, students in schools with school health programs were twice (aOR = 2.24: 95%CI; 1.24-4.06) more likely to know that cervical cancer is preventable. Conclusion: Secondary school girls need information on cervical cancer risk factors and approaches to prevention so that they may avoid exposures to the risk factors and promptly seek and undertake preventive approaches including HPV vaccinations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. A histopathological review of gynaecological malignancies in Katsina state North-Western Nigeria.
- Author
-
Usman, Asma'u, Bello, Shamsu Sahalu, Abdurrahman, Aisha, Rasheed, Fatima Abubakar, Adam, Shuaibu, and Dahiru, Abubakar
- Subjects
- *
HUMAN papillomavirus , *GENITALIA , *GYNECOLOGIC cancer , *CERVIX uteri , *PUBLIC hospitals , *GENITAL warts - Abstract
Background: Gynaecological cancers, which affect the female genital tract, constitute a significant public health problem, especially in developing countries. Some of these malignancies have known aetiology and premalignant stages making them preventable. Understanding the burden of gynaecological malignancies in our environment will provide baseline information and help form strategies for their control. Aim: To describe the histological subtypes of gynaecological cancers, their frequency and age distribution trends in Katsina State over the 10-year study period. Methods: This was a 10-year retrospective cross-sectional multicenter study of all histologically diagnosed gynaecological cancer cases seen from 1st January 2012 to 31st December 2021 at Federal Teaching Hospital Katsina, General Hospital Katsina and General Amadi Rimi Specialist Hospital Katsina. Data for this study were extracted from departmental record registers of the pathology laboratories of the corresponding hospitals whose laboratories provide pathology services to the State. Cancer distribution over the years was sorted based on the primary site of diagnosis, histological diagnosis and age. Data were analysed using Statistical Package for Social Science version 28 and results were presented in tables and charts. Results: Two thousand three hundred and fifty-nine cancers were seen over the 10-year study period. Of these cases, 58.4% (n = 1,378) were females. Gynaecological malignancies accounted for 18.7% (441/2,359) of all cancers and 32.0% (441/1,378) of all female cancers. The highest frequency of gynaecological cancers was seen in women who were within the age groups of 40-49 and 50-59, and the lowest was seen in women who were ≥90 years old. The mean age was 48.9 ± 14.9 years. The most common site of gynaecological malignancies was the cervix uteri (n = 262, 59.4%) followed by the ovary (n = 106, 24.0%). Other sites in descending order were corpus uteri (n = 29, 6.6%), vulva (n = 9, 2.0%) and vagina (n = 2, 0.5%). The most common histo-morphologic subtypes were large-cell keratinizing squamous cell carcinoma in the cervix, large-cell non-keratinizing squamous cell carcinoma in the cervix and cystadenocarcinoma in the ovary. Choriocarcinoma was found in 33 cases (7.5%). Conclusion: This study demonstrated the various histotypes of gynaecological malignancies and their trends in Katsina state. The leading cancer was found to be cervical cancer which is mainly preventable. It is hoped that data from this study will provide a basis for making and implementing policies and strategies to lessen the problems of gynaecological malignancies through regular screening programs, especially for cervical cancer and accepting human papilloma virus (HPV) vaccination take-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Prevalence of human papillomaviruses in self-collected samples among women attending antenatal care in Ethiopia: a cross-sectional study.
- Author
-
Runge, Isabel, Klein, Johanna M. A., Pannen, Ann-Katrin, Abera, Semaw, Wakuma, Tariku, Gebrehiwot, Yirgu, Unverzagt, Susanne, Wienke, Andreas, Thomssen, Christoph, Kaufmann, Andreas M., Jemal, Ahmedin, Abebe, Tamrat, Holzinger, Dana, Waterboer, Tim, Höfler, Daniela, Addissie, Adamu, and Kantelhardt, Eva Johanna
- Subjects
- *
HUMAN papillomavirus , *CITY dwellers , *RURAL women , *HEALTH facilities , *ETHIOPIANS , *GENITAL warts - Abstract
Cervical cancer is the second most commonly diagnosed cancer in women in Ethiopia. However, data are limited on the prevalence of human papillomavirus (HPV) genotypes. Self-sampled vaginal lavages were obtained consecutively from 783 women attending 7 health facilities across Ethiopia. Genotype prevalence was assessed by Multiplex- Papillomavirus-Genotyping which detects and individually identifies 51 genotypes and 3 subtypes. Genotype-specific prevalence was described and associations with known risk factors were analysed. The overall HPV prevalence (age range 18-45) was 33.1% (95% confidence interval (CI) 29.8-36.4). The prevalence of HPV was different in the rural and urban population with 17.6% (95%CI 11.6-23.7) and 36.8% (95%CI 33.1-40.6) (p < 0.001 chi-square test), respectively. The most common high-risk types were HPV 16 (6.6%), followed by HPV 52 (4.3%), 51 and 39 (both 2.9%). Urban women compared to rural women had a higher risk of being HPV positive (odds ratio 2.36 (95% CI 1.47-3.79; p < 0.001). Age at sexual debut ≤15 years and polygamous husband (in urban women) also increased the risk of being HPV positive nearly two-fold. The high prevalence of hr-HPV in Ethiopian women in the reproductive age group shows the need for screening programs. The nonavalent HPV vaccine covers the most prevalent hr-HPV genotypes as found in this study and can therefore be used effectively. Since antenatal care is the bestutilised health service, implementing self-sampled vaginal lavage could be an opportunity for screening in this age group. Screening algorithms and triage still need to be defined to avoid over-treatment in these women. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Challenges of emotional support for women with genital warts: A qualitative study
- Author
-
Mohadese Adeli, Shadab Shahali, and Lida Moghaddam-Banaem
- Subjects
genital warts ,human papillomavirus ,emotional support ,emotional relationships ,Medicine ,Medicine (General) ,R5-920 - Abstract
Objective(s): Genital warts, in addition to being important as a sexually transmitted disease, can alter the emotional support of affected women and threaten couples' emotional relationships. This study was designed with a qualitative approach to investigate the challenges of emotional support for women with genital warts. Methods: The present qualitative study was performed from January 2019 to February 2020 in the dermatology clinic of Razi Hospital in Tehran, Iran, with purposive sampling of 16 women with genital warts. Data were collected through unstructured interviews and analyzed using conventional content analysis approach. Results: After data analysis, a total of 182 codes, 8 subcategories, 3 main categories and 1 theme were obtained. The theme namely "Emotional Support Challenges" included the three main categories of "emotional relationship change", "disclosing the disease to seek support" and "worry for labeling and judgment". Conclusion: The results of the present study showed the challenges of emotional support for women after contracting genital warts. After contracting genital warts, women experienced emotional deterioration. However, receiving emotional support from family members or friends instead of their partner accompanied by the worry of being judged and stigmatization.
- Published
- 2024
43. Clinical evaluation of an artificial intelligence-assisted cytological system among screening strategies for a cervical cancer high-risk population.
- Author
-
Yang, Wen, Jin, Xiangshu, Huang, Liying, Jiang, Shufang, Xu, Jia, Fu, Yurong, Song, Yaoyao, Wang, Xueyan, Wang, Xueqing, Yang, Zhiming, and Meng, Yuanguang
- Subjects
- *
MEDICAL screening , *CERVICAL cancer , *HUMAN papillomavirus , *RECEIVER operating characteristic curves , *GENITAL warts , *EARLY detection of cancer - Abstract
Background: Primary cervical cancer screening and treating precancerous lesions are effective ways to prevent cervical cancer. However, the coverage rates of human papillomavirus (HPV) vaccines and routine screening are low in most developing countries and even some developed countries. This study aimed to explore the benefit of an artificial intelligence-assisted cytology (AI) system in a screening program for a cervical cancer high-risk population in China. Methods: A total of 1231 liquid-based cytology (LBC) slides from women who underwent colposcopy at the Chinese PLA General Hospital from 2018 to 2020 were collected. All women had received a histological diagnosis based on the results of colposcopy and biopsy. The sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), false-positive rate (FPR), false-negative rate (FNR), overall accuracy (OA), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and Youden index (YI) of the AI, LBC, HPV, LBC + HPV, AI + LBC, AI + HPV and HPV Seq LBC screening strategies at low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) thresholds were calculated to assess their effectiveness. Receiver operating characteristic (ROC) curve analysis was conducted to assess the diagnostic values of the different screening strategies. Results: The Se and Sp of the primary AI-alone strategy at the LSIL and HSIL thresholds were superior to those of the LBC + HPV cotesting strategy. Among the screening strategies, the YIs of the AI strategy at the LSIL + threshold and HSIL + threshold were the highest. At the HSIL + threshold, the AI strategy achieved the best result, with an AUC value of 0.621 (95% CI, 0.587–0.654), whereas HPV testing achieved the worst result, with an AUC value of 0.521 (95% CI, 0.484–0.559). Similarly, at the LSIL + threshold, the LBC-based strategy achieved the best result, with an AUC of 0.637 (95% CI, 0.606–0.668), whereas HPV testing achieved the worst result, with an AUC of 0.524 (95% CI, 0.491–0.557). Moreover, the AUCs of the AI and LBC strategies at this threshold were similar (0.631 and 0.637, respectively). Conclusions: These results confirmed that AI-only screening was the most authoritative method for diagnosing HSILs and LSILs, improving the accuracy of colposcopy diagnosis, and was more beneficial for patients than traditional LBC + HPV cotesting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Initial Evidence of a Possible Effect of HPV Vaccination on Cancer Incidence in Germany.
- Author
-
Grieger, P., Eisemann, N., Hammersen, F, Rudolph, C., Katalinic, A., and Waldmann, A.
- Subjects
SEXUALLY transmitted diseases ,HUMAN papillomavirus ,HUMAN papillomavirus vaccines ,CERVICAL cancer diagnosis ,CANCER vaccines ,GENITAL warts - Abstract
Background: Infection with human papillomavirus (HPV) is one of the more common sexually transmitted diseases in Germany. Vaccination against HPV was introduced in Germany in 2007. In this study, we sought to detect a population-based decline in the incidence of cervical cancer in women under age 30 who were eligible for vaccination in the first 11 years after its introduction. Methods: Data on new diagnoses of HPV-associated cervical cancer from 2004 to 2018 were obtained from the cancer registries of the German federal states (Bundesländer) through the German Center for Cancer Registry Data (ZfKD). Trends in the incidence of invasive and in situ cervical cancer were determined with log-linear joinpoint regression and age--period--cohort models. Results: The incidence of cervical cancer, which had been rising in the previous decades, has been falling since 2010, with a marked decline among women in all age groups eligible for vaccination (e.g., from 70.0 to 41.8 cases per 100 000 persons per year from 2010 to 2018 in women aged 24 to 26). Women born in 1992 were the first to become eligible for vaccination and have a 24% lower incidence than the reference cohort of women born in 1989 (relative risk 0.76, 95% confidence interval [0.68; 0.86]). Larger effects were found in later birth cohorts, in which vaccination was more widespread. Conclusion: Eleven years after the introduction of HPV vaccination, a drop in the incidence of cervical cancer was observable at the population level in the birth cohorts eligible for vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Incidence distributions, risk factors and trends of vaginal cancer: A global population‐based study.
- Author
-
Huang, Junjie, Chan, Sze Chai, Pang, Wing Sze, Mak, Fung Yu, Fung, Yat Ching, Lok, Veeleah, Zhang, Lin, Lin, Xu, Lucero‐Prisno, Don Eliseo III, Xu, Wanghong, Zheng, Zhi‐Jie, Elcarte, Edmar, Withers, Mellissa, and Wong, Martin C. S.
- Subjects
- *
VAGINAL cancer , *GENITAL warts , *HUMAN papillomavirus , *UNSAFE sex , *HIV , *DISEASE risk factors - Abstract
Objective Design Setting Population Methods Main Outcome Measures Results Conclusions This study aimed to investigate the incidence, risk factors and trends for vaginal cancer.Retrospective observational design.Data were collected from multiple sources, including the Global Cancer Observatory, Cancer Incidence in Five Continents Plus, Global Burden of Disease, World Bank and the United Nations.Individuals diagnosed with vaginal cancer.The study collected data on vaginal cancer from the specified sources. The age‐standardised rate (ASR) of vaginal cancer was calculated for different regions and age groups. Multivariable and univariable linear regression analyses were performed to examine the associations between risk factors and the incidence of vaginal cancer. Trend analysis was conducted using joinpoint regression analysis, and the average annual percentage change (AAPC) was calculated to quantify the temporal trend.The main outcome measures of the study were the incidence of vaginal cancer, risk factors associated with the disease and the trend of its incidence over time.There were 17 908 newly reported cases of vaginal cancer (ASR = 0.36, 95% CI 0.30–0.44) in 2020, with the highest ASRs reported in South–Central Asia and Southern Africa. Risk factors associated with a higher incidence of vaginal cancer included a higher prevalence of unsafe sex and human immunodeficiency virus (HIV) infection. The temporal trend showed an overall rising incidence globally, with Iceland (AAPC = 29.56, 95% CI 12.12–49.71), Chile (AAPC = 22.83, 95% CI 13.20–33.27), Bahrain (AAPC = 22.05, 95% CI 10.83–34.40) and the UK (AAPC = 1.40, 95% CI 0.41–2.39) demonstrating the most significant rising trends.The significant regional disparities and risk factors associated with vaginal cancer underscore the necessity for targeted interventions and education, particularly in regions with a lower human development index (HDI) and a higher prevalence of human papillomavirus (HPV) infection. The increasing incidence trend emphasises the need for enhanced HPV vaccination rates to prevent the development of vaginal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Performance of P16INK4a immunocytochemical stain in facilitating cytology interpretation of HSIL for HPV-positive women aged 50 and above.
- Author
-
Jun Hou, Hui Du, Chun Wang, Fangbin Song, Xinfeng Qu, and Ruifang Wu
- Subjects
CYTOLOGY ,HUMAN papillomavirus ,CELL morphology ,AGE groups ,CERVICAL intraepithelial neoplasia ,EARLY detection of cancer ,GENITAL warts - Abstract
Background: Few articles have focused on the cytological misinterpretation of high-grade squamous intraepithelial lesion (HSIL). Due to estrogen deficiency, cervical epithelial cells in postmenopausal women tend to show atrophic change that looks like HSIL on Papanicolaou-stained cytology slides, resulting in a higher rate of cytological misinterpretation. P16INK4a immunocytochemical staining (P16 cytology) can effectively differentiate diseased cells from normal atrophic ones with less dependence on cell morphology. Objective: To evaluate the role of P16 cytology in differentiating cytology HSIL from benign atrophy in women aged 50 years and above. Methods: Included in this analysis were women in a cervical cancer screening project conducted in central China who tested positive for high-risk human papillomavirus (hrHPV) and returned back for triage with complete data of primary HPV testing, liquidbased cytology (LBC) analysis, P16 immuno-stained cytology interpretation, and pathology diagnosis. The included patients were grouped by age: ≥50 (1,127 cases) and <50 years (1,430 cases). The accuracy of LBC and P16 cytology in the detection of pathology ≥HSIL was compared between the two groups, and the role of P16 immunostain in differentiating benign cervical lesions from cytology ≥HSIL was further analyzed. Results: One hundred sixty-seven women (14.8%; 167/1,127) in the ≥50 group and 255 (17.8%, 255/1,430) in the <50 group were pathologically diagnosed as HSIL (Path-HSIL). LBC [≥Atypical Squamous Cell Of Undetermined Significance (ASCUS)] and P16 cytology (positive) respectively detected 63.9% (163/255) and 90.2% (230/255) of the Path-≥HSIL cases in the <50 group and 74.3% (124/167) and 93.4% (124/167) of the Path-≥HSIL cases in the ≥50 group. LBC matched with pathology in 105 (41.2%) of the 255 Path-≥HSIL cases in the <50 group and 93 (55.7%) of the 167 Path-≥HSIL cases in the ≥50 group. There were five in the <50 group and 14 in the ≥50 group that were Path-≤LSIL cases, which were interpreted by LBC as HSIL, but negative in P16 cytology. Conclusion: P16 cytology facilitates differentiation of Path-≤LSIL from LBC-≥HSIL for women 50 years of age and above. It can be used in the lower-resource areas, where qualified cytologists are insufficient, as the secondary screening test for women aged ≥50 to avoid unnecessary biopsies and misinterpretation of LBC primary or secondary screening [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Postural Orthostatic Tachycardia Syndrome (POTS) as an Adverse Event to the Human Papilloma Virus (HPV) Vaccine and Its Relationship with Ehlers–Danlos Syndrome (EDS).
- Author
-
Schipperijn, Nicole, Wijesinghe, Megan, Romo, Aisa, and Brooks, Benjamin
- Subjects
- *
POSTURAL orthostatic tachycardia syndrome , *HUMAN papillomavirus , *EHLERS-Danlos syndrome , *GENITAL warts , *PHYSICIANS , *HUMAN papillomavirus vaccines - Abstract
Gardasil 4, a human papilloma virus vaccine, has been shown to protect against various cancers, including cervical cancer. Common side effects include injection site pain, fever, headaches, and muscle aches. In some individuals, the severe side effect of postural orthostatic tachycardia syndrome (POTS) has been reported. POTS is characterized by the abnormal response of lightheadedness, blurry vision, and dizziness while transitioning to an upright posture. POTS predominately affects women, with more than eighty-five (85) percent of POTS patients being female. POTS, on average, takes five years and eleven months to receive diagnosis. Additionally, a strong association between POTS and Ehlers–Danlos Syndrome Type III (EDS) exists. Eighty (80) percent of patients with EDS have POTS. This severe side effect indicates that providers need to be aware of this strong association of HPV vaccinations and POTS. In this report, we will present a case of a young women with a past medical history significant for EDS type III who was diagnosed with POTS after receiving Gardasil 4 vaccination. This case demonstrates the need for physicians to be aware of the association of POTS with EDS type III and HPV vaccination. Physician awareness of the associations, signs, and symptoms of POTS and earlier testing at the first presentation of signs and symptoms will limit the negative impact on patient's quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer.
- Author
-
Arbyn, Marc, Rousta, Pegah, Bruni, Laia, Ask, Lina Schollin, and Basu, Partha
- Subjects
- *
GENITAL warts , *HUMAN papillomavirus vaccines , *CERVICAL cancer , *CANCER invasiveness , *HEPATITIS B vaccines , *BCG vaccines , *DATA protection - Abstract
A recent study published in the Journal of the National Cancer Institute confirms the effectiveness of the human papillomavirus (HPV) vaccine in preventing invasive cervical cancer. The study, conducted in Scotland, linked vaccination records with cervical cancer screening data and the national cancer registry. It found that girls who were immunized with the bivalent HPV vaccine at the age of 12 to 13 had excellent protection against invasive cervical cancer. The study adds to the existing evidence from intervention trials and population-based surveillance, supporting the high level of effectiveness of HPV vaccination in preventing cervical cancer. The findings highlight the importance of vaccinating teenagers and offer recommendations for routine vaccination programs. The study also emphasizes the need for legal frameworks and administrative solutions to facilitate the monitoring of preventive health programs through the linkage of individual patient data. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
49. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation.
- Author
-
Palmer, Tim J, Kavanagh, Kimberley, Cuschieri, Kate, Cameron, Ross, Graham, Catriona, Wilson, Allan, and Roy, Kirsty
- Subjects
- *
GENITAL warts , *HUMAN papillomavirus vaccines , *CERVICAL cancer , *CANCER invasiveness , *VACCINE effectiveness , *IMMUNIZATION - Abstract
Background High-risk human papillomavirus causes cervical cancer. Vaccines have been developed that significantly reduce the incidence of preinvasive and invasive disease. This population-based observational study used linked screening, immunization, and cancer registry data from Scotland to assess the influence of age, number of doses, and deprivation on the incidence of invasive disease following administration of the bivalent vaccine. Methods Data for women born between January 1, 1988, and June 5, 1996, were extracted from the Scottish cervical cancer screening system in July 2020 and linked to cancer registry, immunization, and deprivation data. Incidence of invasive cervical cancer per 100 000 person-years and vaccine effectiveness were correlated with vaccination status, age at vaccination, and deprivation; Kaplan Meier curves were calculated. Results No cases of invasive cancer were recorded in women immunized at 12 or 13 years of age irrespective of the number of doses. Women vaccinated at 14 to 22 years of age and given 3 doses of the bivalent vaccine showed a significant reduction in incidence compared with all unvaccinated women (3.2/100 000 [95% confidence interval (CI) = 2.1 to 4.6] vs 8.4 [95% CI = 7.2 to 9.6]). Unadjusted incidence was significantly higher in women from most deprived (Scottish Index of Multiple Deprivation 1) than least deprived (Scottish Index of Multiple Deprivation 5) areas (10.1/100 000 [95% CI = 7.8 to 12.8] vs 3.9 [95% CI = 2.6 to 5.7]). Women from the most deprived areas showed a significant reduction in incidence following 3 doses of vaccine (13.1/100 000 [95% CI = 9.95 to 16.9] vs 2.29 [95% CI = 0.62 to 5.86]). Conclusion Our findings confirm that the bivalent vaccine prevents the development of invasive cervical cancer and that even 1 or 2 doses 1 month apart confer benefit if given at 12-13 years of age. At older ages, 3 doses are required for statistically significant vaccine effectiveness. Women from more deprived areas benefit more from vaccination than those from less deprived areas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Factors Associated with HPV Genital Warts: A Self-Reported Cross-Sectional Study among Students and Staff of a Northern University in Nigeria.
- Author
-
Ogbolu, Melvin Omone, Eniade, Olanrewaju D., Majiya, Hussaini, and Kozlovszky, Miklós
- Subjects
- *
CHI-squared test , *GENITAL warts , *HUMAN papillomavirus , *SOCIAL media , *SEXUALLY transmitted diseases , *LOGISTIC regression analysis - Abstract
The menace of human papillomavirus (HPV) infections among low- and middle-income countries with no access to a free HPV vaccine is a public health concern. HPV is one of the most common sexually transmitted infections (STIs) in Nigeria, while the most known types of HPV genotypes being transmitted are the high-risk HPV-16 and 18 genotypes. In this study, we explored the predictors of self-reported HPV infections and HPV genital warts infection among a population of students, non-academic staff, and academic staff of Ibrahim Badamasi Babangida (IBB) University located in Lapai, Nigeria. We also assessed their knowledge about HPV infections and genotypes, and sexual behaviors. An online cross-sectional study was conducted by setting up a structured questionnaire on Google Forms and it was distributed to the university community via Facebook and other social media platforms of the university. The form captured questions on HPV infection, and knowledge about HPV infection and genotypes, as well as the sexual health of the participants. All variables were described using frequencies and percentage distribution; chi-squared test statistics were used to explore the association between HPV infection (medical records of HPV infection) and the participants' profile, and a logistic regression analysis was performed to examine the factors associated with HPV genital warts infection among the population. This study reveals those participants between the ages of 26–40 years (81.3%) and those currently not in a sexually active relationship—single/divorced (26.4%)—who have self-reported having the HPV-16 and -18 genotypes. Moreover, participants between 26–40 years of age (OR: 0.45, 95%CI: 0.22–0.89) reported themselves to be carriers of HPV genital warts. Therefore, this study reveals the factors associated with HPV infection and genital warts peculiar to IBB university students and staff. Hence, we suggest the need for HPV awareness programs and free HPV vaccine availability at IBB university. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.